Grace Therapeutics (GRCE) Market Capitalization (2017 - 2026)

Grace Therapeutics has disclosed Market Capitalization across 10 years of filings, most recently posting $36.9 million for Q2 2026.

• In Q2 2026, Market Capitalization fell 10.05% year-over-year to $36.9 million; the TTM figure through Jun 2026 stood at $36.9 million (down 10.05% YoY), while the FY2026 annual figure was $74.2 million, up 137.2% from the prior year.
• Market Capitalization came in at $36.9 million for Q2 2026 at Grace Therapeutics, down from $74.2 million in the prior quarter.
• In the past five years, Market Capitalization ranged from a high of $74.2 million in Q1 2026 to a low of $20.5 million in Q1 2023.
• Average Market Capitalization over 5 years is $35.2 million, with a median of $31.8 million recorded in 2024.
• Year-over-year, Market Capitalization plunged 67.21% in 2022 and surged 137.2% in 2026.
• Over 5 years, Market Capitalization stood at $22.3 million in 2022, then increased by 21.78% to $27.2 million in 2023, then soared by 39.61% to $37.9 million in 2024, then surged by 41.18% to $53.5 million in 2025, then sank by 31.0% to $36.9 million in 2026.
• Per Business Quant data, the three most recent Market Capitalization figures were $36.9 million in Q2 2026, $74.2 million in Q1 2026, and $53.5 million in Q4 2025.